Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
Patient took 3 capsules of Vivotif three days in a row; Case reference number US-BN-2025-001775 is a spontaneous case initially received from other health professional via Bavarian Nordic (reference number: CASE-000628) on 06-Nov-2025 and concerns a patient of an unspecified age and gender. The patient's medical history and concomitant medication were not reported. On unspecified date, the patient was vaccinated with first and second dose of Vivotif (batch number: unknown) at an unknown dose, route and site of administration for an unknown indication. On 06-Nov-2025, the patient was vaccinated with third dose of Vivotif (batch number: unknown) at an unknown dose, route and site of administration for an unknown indication. Patient took three capsules of Vivotif three days in a row. (explicitly coded as 'inappropriate schedule of product administration'). Fourth capsule had not been taken yet. At the time of initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. No further information was provided.; Reporter's Comments: This case concerns a patient of an unspecified age and gender, who had taken three capsules of Vivotif vaccine, three days in a row, for an unknown indication, which is considered as inappropriate schedule of product administration. At the time of initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed as per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a patient of an unspecified age and gender, who had taken three capsules of Vivotif vaccine, three days in a row, for an unknown indication, which is considered as inappropriate schedule of product administration. At the time of initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed as per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.